New treatments of chronic hepatitis C

作者：Fontaine Helene^*; Sogni Philippe; Pol Stanislas

来源：Presse Medicale, 2012, 41(2): 138-145.

DOI：10.1016/j.lpm.2011.09.006

New treatments of chronic hepatitis C %26lt;br%26gt;The current treatment of chronic hepatitis C since several years, the association of pegylated interferon and ribavirine, allows to obtain a virological eradication in 55% of patients, all genotypes and 45% of those infected with the genotype 1, the. most prevalent. %26lt;br%26gt;The cure, defined by an undetectable viremia 24 weeks after the discontinuation of treatment is associated to a improvement of the prognosis of the patients with a decrease of mortality and morbidity. %26lt;br%26gt;The development of news antiviral C molecules, efficient against the genotype 1, two protease inhibitors, boceprevir or telaprevir (which approval has been recently obtained), in association with pegylated interferon and ribavirine, allows to obtain a viral eradication in 70 to 75% of cases, with a reduction of treatment duration to 24 weeks in half of patients. This evolution will modify the therapeutic indications, the therapeutic schemas, the virologic follow-up, the risk factors of sustained virological reponse, the tolerance with the appearance of new adverse effects.

• 出版日期2012-2